is anti-mullerian hormone a good diagnostic marker for adolescent and young adult patients with polycystic ovary syndrome?

Clicks: 267
ID: 163497
2015
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #14 of 41 articles by views in iafor journal of ethics, religion & philosophy

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Objective: To evaluate serum anti-Mullerian hormone (AMH) levels in adolescent and young adult (AYA) Turkish patients with Polycystic ovary syndrome (PCOS), and to determine whether it had a diagnostic value. Materials and Methods: A total of 90 AYA patients were recruited for this study. The study group consisted of 43 patients diagnosed as having PCOS, and the control group comprised 47 age-matched patients. The diagnosis of PCOS was made in accordance with the recent Amsterdam European Society of Human Reproduction and Embryology/American Society for Reproductive Medicine PCOS consensus workshop group’s proposal that all three of the Rotterdam criteria for diagnosing PCOS in adolescents be present. In all patients, serum AMH levels were measured using enzyme-linked immunosorbent assay. Receiver operator characteristics (ROC) curve analysis was performed to reveal diagnostic potential of AMH. Results: Serum AMH levels were higher in the PCOS group compared with controls, but the difference was not statistically significant (10.1±6.9 ng/mL vs. 9.4±5.5 ng/mL, p=0.198). There was a significant age-related decrease in AMH levels in both the study and control groups (r=-0.331, p=0.001). There was also a significant inverse correlation between serum AMH and follicle-stimulating hormone levels in all patients (r=-0.227, p=0.031). ROC analyses demonstrated that the area under the curve indicative of AMH value for discriminating PCOS was 0.579 with a 95% confidence interval of 0.453-0.705 (p=0.198). The cut-off value according to the highest Youden index was calculated to be 14.0 ng/mL with a sensitivity of 48.8% and specificity of 77.1%. Conclusion: Serum AMH levels are slightly higher in AYA patients with PCOS than in controls. However, AMH is not a good marker for the diagnosis of PCOS in AYA patients.
Reference Key
tokmak2015turkishis Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors ;Aytekin Tokmak;Hakan Timur;Rıfat Taner Aksoy;Mehmet Çınar;Nafiye Yılmaz
Journal iafor journal of ethics, religion & philosophy
Year 2015
DOI
10.4274/tjod.21549
URL
http://www.tjoddergisi.org/archives/archive-detail/article-preview/s-anti-mullerian-hormone-a-good-diagnostic-marker-/11498
Keywords
Adolescent anti-müllerian hormone

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.